Incidence and predictors of restenosis after sirolimus-eluting stent implantation in high-risk patients

Predictive Factors of Restenosis After Coronary Implantation of Sirolimus- or Paclitaxel-Eluting Stents

“…In contrast, Kuchulakanti et al 26 found no difference in target lesion revascularization rates between 403 patients with diabetes mellitus and 750 patients without diabetes mellitus. Similarly, in the studies of Berenguer et al 27 and Migliorini et al, 28 diabetes mellitus was not an independent predictor of angiographic and clinical restenosis. Comparable rates of angiographic restenosis rates also were found among patients with (6.4%) and without (8.4%) diabetes mellitus in the diabetes substudy of TAXUS IV trial.…”

Rotational atherectomy for fibro‐calcific coronary artery disease in drug eluting stent era: Procedural outcomes and angiographic follow‐up results

“…Previous studies have shown several predictors of instent restenosis following stent implantation [10,11], including coronary calcification. The similar data from the calcified coronary lesions is lacking.…”

“…Coronary artery stenting with drug eluting stents has shown to be effective in reducing restenosis and target vessel revascularization rates in several randomized trials in wide variety of clinical situations [1][2][3][4][5][6][7][8][9].The risk of restenosis remains high after coronary stenting in complex lesions such as long lesions, fibrocalcific lesions, bifurcations, ostial, and vein graft lesions [10,11]. Adequate lesion preparation before coronary stenting remains crucial in patients with complex lesions to improve outcomes.…”

Predictors of death after coronary stenting with sirolimus-eluting stent in high-risk patients

“…The characteristics of the registry have been previously described [14]. In summary, from May 2002 to August 2003, 233 patients with a total of 265 complex lesions (proximal LAD lesions, long lesions, left main trunk lesions, calcified lesions, ostial lesions, occluded coronary arteries, bifurcations and restenotic lesions) in native coronary arteries and demonstrated myocardial ischaemia were treated by implantation of SES (Cypher®, Cordis, Johnson & Johnson Company) and were included in a prospective registry to analyze their clinical evolution.…”

“…Predictors of restenosis and target lesion revascularization have been widely evaluated in recent years [13][14][15]. However, it might be more important to know which factors contribute to death during follow up after coronary stenting with DES.…”